Genentech Inc. said late Wednesday it has settled a long-running fight with MedImmune Inc. over one of the cornerstone patents of the biotech industry. The patent, Cabilly II, covers certain manufacturing methods for monoclonal antibodies, a type of bioengineered protein that Genentech of South San Francisco, Calif., has turned into several lucrative medicines, including the cancer treatments Avastin and Herceptin. MedImmune filed its original complaint in April 2003.
June 12, 2008 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Genentech Inc. said late Wednesday it has settled a long-running fight with MedImmune Inc. over one of the cornerstone patents of the biotech industry.
The patent, Cabilly II, covers certain manufacturing methods for monoclonal antibodies, a type of bioengineered protein that Genentech of South San Francisco, Calif., has turned into several lucrative medicines, including the cancer treatments Avastin and Herceptin. MedImmune filed its original complaint in April 2003.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
